It’s too early to say CBD helps against Covid; Pfizer and BioNTech begin trial of Omicron-based vaccine

Though it's too soon to tell whether CBD helps against Covid-19, researchers worry that won't stop CBD makers. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        It's too early to tell whether CBD helps against Covid-19 — but researchers worry that won't stop CBD makers By Nicholas Florko and Andrew Joseph Justin Sullivan/Getty Images It's too early to tell whether CBD helps against Covid-19 — but researchers worry that won't stop CBD makers. Read More STAT+: Insulin giants Eli Lilly and Novo Nordisk boosted their lobbying spending as Democrats eyed pricing reform By Rachel Cohrs JEAN-FRANCOIS MONIER/AFP/Getty Images As Democrats considered cracking down on insulin prices, manufacturing giants Eli Lilly and Novo Nordisk increased their lobbying spending. Read More As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear By Matthew Herper Cindy Ord/Getty Images for Pfizer/BioNTech A new study will look at the safety, immunogenicity, and tolerability of an Omicron-based vaccine compared to the original vaccine. Read More Sponsor content by Seqirus What makes influenza prevention so challenging? Paving the way with a new innovative platform On the front line of protection against influenza is Seqirus, one of the largest influenza vaccine providers in the world. The company is paving the way by advancing the next generation of messenger RNA (mRNA) vaccine technology: self-amplifying mRNA (sa-mRNA). To learn more about Seqirus' mission to fight against seasonal and pandemic influenza, visit the Seqirus website. STAT+: Pivotal study shows Sierra Oncology drug improves anemia and other symptoms of myelofibrosis By Adam Feuerstein Adobe Based on the positive study results, Sierra intends to file a U.S marketing application for its drug during the second quarter. Read More STAT+: Can open datasets help machine learning solve medical mysteries? By Katie Palmer Courtesy Ziad Obermeyer Nightingale Open Science wants to accelerate ethical AI in medicine by doing the hard work of making health care data accessible. Read More Opinion: STAT+: What's blocking health care boards' progress in diversity, equity, and inclusion? By Jim King and Philip Burton Adobe Key executives from 25 leading health systems offer insight into their goals for making health care boards more diverse and inclusive. Read More STAT+: What risks? FDA scolds Lilly for misleading Instagram post about a best-selling diabetes drug By Ed Silverman The FDA rebuked Eli Lilly for running a misleading Instagram post that omitted risk information about a best-selling diabetes drug. Read More Opinion: Learning from Covid-19 requires a modeling renaissance By Amir Mokhtari Adobe The future of modeling will be forever shaped by Covid-19, with a shift toward using AI and a focus on local decision-making. Read More Tuesday, January 25, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser